Information Provided By: 
Fly News Breaks for October 9, 2018
SNY, PRNB
Oct 9, 2018 | 07:54 EDT
Baird analyst Brian Skorney started Principia Biopharma (PRNB) with an Outperform rating and $50 price target, stating that its BTK inhibitor partnered with Sanofi (SNY) for multiple sclerosis has blockbuster potential. He also believes PRN1008, which is entering Phase 3, has a worldwide opportunity over $500M in pemphigus that would also open the door for a host of other indications.
News For PRNB;SNY From the Last 2 Days
There are no results for your query PRNB;SNY
